Skip to content
EntityQ5268320· pop 8· linked from 127 articles

dexelvucitabine

Sign in to save

Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.

Research

39 papers

via PubMed

Wikidata facts

Mass
227.071
Show 5 more facts
stereoisomer of
elvucitabine
canonical SMILES
C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F
chemical formula
C₉H₁₀FN₃O₃
isomeric SMILES
C1=C[C@@H](O[C@@H]1CO)N2C=C(C(=NC2=O)N)F
Commons category
Dexelvucitabine
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

1 sections
Contents
  • References

Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.

On April 3, 2006, Pharmasset and Incyte, the pharmaceutical companies developing dexelvucitabine, announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme lipase in the bloodstream) in a phase II trial.

Excerpted from Wikipedia’s “dexelvucitabine” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0